Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 7/20 | 0.69 |
| ▸ | HTT | P42858 | 4/20 | 0.69 |
| ▸ | AHR | P35869 | 1/20 | 0.64 |
| ▸ | RAB9A | P51151 | 6/20 | 0.64 |
| ▸ | NPC1 | O15118 | 5/20 | 0.64 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.64 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.63 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.63 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.62 |
| ▸ | MEN1 | O00255 | 6/20 | 0.60 |
| ▸ | LMNA | P02545 | 4/20 | 0.60 |
| ▸ | POLB | P06746 | 1/20 | 0.60 |
| ▸ | TP53 | P04637 | 1/20 | 0.60 |
| ▸ | TSHR | P16473 | 1/20 | 0.58 |
| ▸ | MAPT | P10636 | 4/20 | 0.58 |
| ▸ | ATM | Q13315 | 1/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.56 |
| ▸ | PKM | P14618 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5950287 | 0.88 | TAAR1 (0.63) | KMT2AHTTAHRRAB9ANPC1 | |
| SCHEMBL22926423 | 0.84 | HTT (0.70) | KMT2AHTTAHRRAB9ANPC1 | |
| SCHEMBL30051982 | 0.83 | MEN1 (0.77) | KMT2AHTTRAB9ANPC1KDM4E | |
| SCHEMBL9637653 | 0.83 | MEN1 (0.77) | KMT2AHTTRAB9ANPC1KDM4E | |
| SCHEMBL21834403 | 0.82 | NPC1 (0.81) | KMT2AHTTRAB9ANPC1SMN1; SMN2 | |
| SCHEMBL10665495 | 0.82 | RAB9A (0.79) | KMT2AHTTAHRRAB9ANPC1 | |
| SCHEMBL22926342 | 0.82 | HTT (1.00) | KMT2AHTTAHRRAB9ANPC1 | |
| SCHEMBL17079604 | 0.82 | MEN1 (0.74) | KMT2AHTTAHRRAB9ANPC1 | |
| Hydrochloric Acid SCHEMBL29388210 | 0.82 | MEN1 (0.74) | KMT2AHTTRAB9ANPC1KDM4E | |
| Bromide SCHEMBL29417998 | 0.82 | MEN1 (0.74) | KMT2AHTTRAB9ANPC1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210022340-A1 | USE OF PYRIDINE UREA COMPOUND HAVING SNAIL-KILLING ACTIVITY | THE NATIONAL INSTITUTE OF PARASITIC DISEASES, CHINESE CENTER FOR DISEASE CONTROL AND PREVENTION (CN) | 2021-01-28 | — | — | US | disclosed |
| US-8143293-B2 | disease caused by c-Abl kinase, c-Kit kinase, oncogenic forms, aberrant fusion proteins and polymorphs; 1-(3-t-butylisoxazol-5-yl)-3-(2-fluoro-4-(2-(1-methyl-1H-pyrazol-4-yl)pyridin-4-yloxy)phenyl)urea | DECIPHERA PHARMACEUTICALS, LLC (US) | 2012-03-27 | — | — | US | disclosed |
| US-20110189167-A1 | Methods and Compositions for the Treatment of Myeloproliferative Diseases and other Proliferative Diseases | DECIPHERA PHARMACEUTICALS, LLC | 2011-08-04 | — | — | US | disclosed |
| US-20080261961-A1 | KINASE INHIBITORS USEFUL FOR THE TREATMENT OF MYLEOPROLIFIC DISEASES AND OTHER PROLIFERATIVE DISEASES | DECIPHERA PHARMACEUTICALS, LLC (US) | 2008-10-23 | — | — | US | disclosed |
| US-20080261965-A1 | KINASE INHIBITORS USEFUL FOR THE TREATMENT OF MYLEOPROLIFIC DISEASES AND OTHER PROLIFERATIVE DISEASES | DECIPHERA PHARMACEUTICALS, LLC (US) | 2008-10-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110189167-A1 | Methods and Compositions for the Treatment of Myeloproliferative Diseases and other Proliferative Diseases | MCL1, NRAS, ABL1 | KMT2A 1819/4885HTT 3179/4885AHR 3628/4885 |
| US-20210022340-A1 | USE OF PYRIDINE UREA COMPOUND HAVING SNAIL-KILLING ACTIVITY | SLC14A1, UACA, UROD | KMT2A 4029/4885HTT 4212/4885AHR 3321/4885 |
| US-20080261965-A1 | KINASE INHIBITORS USEFUL FOR THE TREATMENT OF MYLEOPROLIFIC DISEASES AND OTHER PROLIFERATIVE DISEASES | KIT, PRKACA, BRAF | KMT2A 658/4885HTT 1939/4885AHR 1838/4885 |
| US-20080261961-A1 | KINASE INHIBITORS USEFUL FOR THE TREATMENT OF MYLEOPROLIFIC DISEASES AND OTHER PROLIFERATIVE DISEASES | KIT, BRAF, RET | KMT2A 743/4885HTT 1801/4885AHR 2098/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.